CONTENTS
· Invitation
· Faculty
· Scientific Agenda
· Continuing
  Medical Education
· Who Should Attend?
· Objectives
· Registration
· Hotel
  Accommodations
· Organizer

Program Chairs

Chair:
Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Co-Chair, Leukemia Session:
Richard R. Furman, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Co-Chair, Lymphoma Session:
John P. Leonard, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Co-Chair, Myeloma Session:
Ruben Niesvizky, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Click here to register for this program

It is our pleasure to invite you to join us at Lymphoma & Myeloma 2007. This fall’s conference, October 18-20, 2007 at the Waldorf=Astoria in New York City, promises to be our most exciting meeting yet!

Since its inception in 2000, this conference has grown to over 700 attendees and has become the premier forum for discussion on the latest advances in lymphoma and myeloma. Guided by the expertise of the leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, attendees will receive a thorough understanding of the evolution of thought and therapy of the topics under discussion.

With an integrated, interdisciplinary approach – through the discussion of clinical controversies, debates and examinations of current treatment regimens – this conference will provide for a stimulating and interactive forum for attendees from all relevant medical specialties.And with the benefit of visiting New York during one of the most beautiful times of year, this conference will be the perfect chance for you to get away and enjoy a weekend of learning in the capital city of the world.We cordially welcome you to our fair city and promise to reward you with an exciting, informative conference!

Sincerely,
Morton Coleman, MD, Chair
Richard R. Furman, MD, Co-Chair, Leukemia Session
John P. Leonard, MD, Co-Chair, Lymphoma Session
Ruben Niesvizky, MD, Co-Chair, Myeloma Session

Raymond Alexanian, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Kenneth C. Anderson, MD, MA
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Bart Barlogie, MD, PhD
University of Arkansas
Medical Center
Little Rock, Arkansas

Maurizio Bendandi, MD, PhD
University Clinic,
Department of Hematology
Pamplona, Spain

Arthur R. Bradwell, MD
University of Birmingham
Birmingham, United Kingdom

Franco Cavalli, MD
Director of the Oncology
Institute of Southern
Switzerland (IOSI)
Bellinzona, Switzerland

Amy Chadburn, MD
Weill Medical College of
Cornell University
New York, New York

Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, New York

Selina Chen-Kiang, PhD
Weill Medical College of
Cornell University
New York, New York

Bruce D. Cheson, MD
Georgetown University
Hospital
Washington, DC

Nicholas Chiorazzi, MD
North Shore - Long Island
Jewish Research Institute
Manhasset, New York

Morton Coleman, MD
Center for Lymphoma
and Myeloma
Weill Medical College of
Cornell University
The New York-Presbyterian
Hospitals
New York, New York
Raymond L. Comenzo, MD
Memorial Sloan-Kettering
Cancer Center
Weill Medical College of
Cornell University
New York, New York

Myron S. Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York

James Dahlberg, PhD
The University of Wisconsin
Madison, Wisconsin

Robert O. Dillman, MD, FACP
Hoag Cancer Center
Newport Beach, California

Angela Dispenzieri, MD
Mayo Clinic
Rochester, Minnesota

Richard I. Fisher, MD
University of Rochester
Medical Center
Rochester, New York

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, Arizona

Francine Foss, MD
Yale Cancer Center
New Haven, Connecticut

Richard R. Furman, MD
Center for Lymphoma
and Myeloma
Weill Medical College of
Cornell University
The New York-Presbyterian
Hospitals
New York, New York

Randy D. Gascoyne, MD
British Columbia Cancer Agency
Vancouver, British Columbia,
Canada

Philip R. Greipp, MD
Mayo Clinic
Rochester, Minnesota

Sandra J. Horning, MD
Stanford University
Medical Center
Stanford, California

Neil E. Kay, MD
Mayo Clinic
Rochester, Minnesota

Lale Kostakoglu, MD
Mount Sinai School
of Medicine
New York, New York

Robert A. Kyle, MD
Mayo Clinic
Rochester, Minnesota

John P. Leonard, MD
Center for Lymphoma
and Myeloma
Weill Medical College of
Cornell University
The New York-Presbyterian
Hospitals
New York, New York

David G. Maloney, MD, PhD
Fred Hutchinson Cancer
Research Center
Seattle, Washington

Ari Melnick, MD
Albert Einstein College
of Medicine
Bronx, New York

Emilio Montserrat, MD
University of Barcelona
Barcelona, Spain

Ruben Niesvizky, MD
Center for Lymphoma
and Myeloma
Weill Medical College of
Cornell University
The New York-Presbyterian
Hospitals
New York, New York

Carol S. Portlock, MD
Memorial Sloan-Kettering
Cancer Center
Weill Medical College of
Cornell University
New York, New York

Kanti Rai, MD
Long Island Jewish
Medical Center
New Hyde Park, New York

S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota

Paul G. Richardson, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

G. David Roodman, MD, PhD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Saul A. Rosenberg, MD
Stanford Comprehensive Cancer Center
Stanford, California

Jia Ruan, MD, PhD
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

John D. Shaughnessy Jr., PhD
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Sonali M. Smith, MD
University of Chicago
Division of Biological Sciences
Chicago, Illinois

David J. Straus, MD
Memorial Sloan-Kettering Cancer Center
Weill Medical College of Cornell University
New York, New York

David Vesole, MD, PhD, FACP
St. Vincent's Comprehensive Cancer Center
New York, New York

Donna Weber, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Wyndham H. Wilson, MD, PhD
National Cancer Institute
Bethesda, Maryland

Anas Younes, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Andrew D. Zelenetz, MD
Memorial Sloan-Kettering Cancer Center
Weill Medical College of Cornell University
New York, New York

Thursday, October 18, 2007
General session

8:00 am
Welcome and introduction
Morton Coleman, MD

Myeloma Section

8:05 am
Introduction
Ruben Niesvizky, MD

Session I: Cell Cycle in Myeloma
Chair: Scott Ely, MD

8:10 am
Plasma cell proliferation, cell cycle: Lessons from clinical trials
Phillip R. Greipp, MD

8:30 am
Cell cycle dysregulation in myeloma: Basic science perspective
Selina Chen-Kiang, PhD

8:50 am
Genomics and the control of cell cycle
John D. Shaughnessy Jr., PhD

9:10 am
Panel discussion

9:25 am
Break

Session II: New Diagnostic and Prognostic Methods--New Dilemmas
Chair: Morton Coleman, MD

9:50 am
PET CT in multiple myeloma
Lale Kostakoglu, MD

10:10 am
Free light chain analysis in multiple myeloma
Arthur R. Bradwell, MD
           
10:30 am
Cytogenetics and molecular prognostic models
Rafael Fonseca, MD

10:50 am
What is the latest in staging and response criteria?
Speaker Invited

11:10 am
Panel discussion

Session III: Atypical Plasmacytic Disorders
Chair: Richard Furman, MD

1:00 pm
POEMS: New advances in diagnosis and treatment
Angela Dispenzieri, MD

Session IV: Treatment I
Chair: Ruben Niesvizky, MD

1:20 pm
IMiDs and other immunomodulator combinations
Ruben Niesvizky, MD

1:40 pm
Proteasome inhibitors and other combinations
Donna Weber, MD

2:00 pm
High risk myeloma: New algorithms and reduced intensity allografts
David Vesole, MD, PhD

2:20 pm
Does transplantation have a future with the advent of novel therapies?
Bart Barlogie, MD, PhD

2:40 pm
Panel discussion

2:55 pm
The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: Joseph Michaeli Award for Contributions to Myeloma
Recipient: Raymond Alexanian, MD

3:05 pm
Break

Session V: Treatment II
Chair: Raymond Alexanian, MD

3:30 pm  
Maximizing benefit, minimizing risk with bisphosphonate therapy
G. David Roodman, MD, PhD  

3:50 pm
Translational research: New drugs
Paul G. Richardson, MD

4:10 pm
Panel discussion

4:30 pm     
Adjourn

Friday, October 19, 2007
General Session

8:00 am
Welcome and introduction
Morton Coleman, MD

Session VI: Waldenstrom’s Macroglobulinemia and Amyloidosis
Chair: Richard Furman, MD

8:05 am     
Diagnostic and response criteria in WM
Robert A. Kyle, MD

8:25 am     
Current treatment strategies for WM
Richard Furman, MD

8:45 am     
Amyloidosis: A risk based model for treatment
Ray Comenzo, MD

9:05 am     
Panel discussion

Session VII: Chronic Lymphocytic Leukemia: Biology
Chair: Richard Furman, MD

9:15 am    
Origin of the CLL lymphocyte: telomere length, kinetics, and markers
Nick Chiorazzi, MD
           
9:35 am     
MicroRNAs: Their role in CLL and cancer biology
James Dahlberg, PhD

9:55 am
New prognostic factors in CLL
Emilio Montserrat, MD

10:15 am
Panel discussion

10:25 am
Break

Session VIII: Chronic Lymphocytic Leukemia: Therapy
Chair: Asher Chanan-Khan, MD

10:45 am
Front-line therapy: What is the current standard of care?
Kanti Rai, MD

11:05 am
Second-line therapy in CLL
Asher Chanan-Khan, MD

11:25 am
Novel agents and combinations in CLL
Neil Kay, MD

11:45 am   
Panel discussion

11:55 am   
Break

Lymphoma Section

1:30 pm
Introduction
John P. Leonard, MD

Session IX: Hodgkin’s Disease
Chair: David J. Straus, MD

1:35 pm     
What is the best management of early stage disease
David J. Straus, MD

1:55 pm     
What is the best management of advanced disease: ABVD, Stanford V, BEACOPP or others?
Sandra J. Horning, MD

2:15 pm
How best to treat lymphocytic-predominant Hodgkin’s disease
Carol S. Portlock, MD

2:35 pm     
Panel discussion

2:50 pm     
The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: John Ultmann Award for Contributions to Lymphoma
Recipient: Saul A. Rosenberg, MD
           
3:00 pm    
Break

Session X: Marginal Zone and Mantle Cell Lymphomas
Chair: Saul A. Rosenberg, MD

3:20 pm     
Optimal management of marginal zone lymphoma
Franco Cavalli, MD

3:40 pm     
Mantle cell lymphoma biology and prognostic indicators
Randy Gascoyne, MD
           
4:00 pm     
Optimal therapy in mantle cell lymphoma
Speaker Invited

4:20 pm
Panel discussion

4:30 pm
Adjourn

Saturday, October 20, 2007
General Session

8:00 am     
Welcome and introduction
Morton Coleman, MD

Session XI: Lymphoma Classification
Chair: Speaker Invited

8:05 am
Update on lymphoma classification
Speaker Invited

Session XII: Aggressive Lymphoma
Chair: Morton Coleman, MD

8:25 am     
Targeting BCL-6 and other peptides in LCL
Ari Melnick, MD

8:45 am
Update in the management of LCL
Richard I. Fisher, MD

9:05 am
PET scanning: Changing the paradigm of therapy for LCL and Hodgkin’s?
Morton Coleman, MD

9:25 am
Panel discussion

9:40 am
Break

Session XIII: Follicular Lymphomas
Chair: John Leonard, MD

10:00 am
Initial therapy for follicular lymphoma
John Leonard, MD

10:20 am
New strategies in the treatment of follicular lymphoma
Bruce Cheson, MD

10:40 am
Clinical benefit of vaccines in follicular lymphoma
Maurizio Bendandi, MD, PhD

11:00 am
Debate:
The case for maintenance anti-CD20 therapy in FL
David Maloney, MD, PhD

The case against maintenance anti-CD20 therapy in FL
Robert O. Dillman, MD

11:20 am
Panel discussion

11:35 am   
Break

AFTERNOON WORKSHOPS

Workshop 1: Lymphoma & Myeloma Agents in Early Development I
Chairs: Ruben Niesvizky, MD and John Leonard, MD

1:15 pm
Heat shock protein 90 inhibitors
Kenneth C. Anderson, MD

1:30 pm
HDAC inhibitors
Francine Foss, MD

1:45 pm
New proteasome inhibitors
Kenneth C. Anderson, MD

2:00 pm
CDK4/6 inhibitors
Selena Chen-Kiang, PhD

2:15 pm
Folate antagonists
Francine Foss, MD

Discussion and 7th Inning Stretch

Workshop 2: Lymphoma & Myeloma Agents in Early Development II
Chairs: Ruben Niesvizky, MD and John Leonard, MD

2:35 pm
Monoclonal antibodies
Myron S. Czuczman, MD

2:50 pm
mTOR inhibitors
Sonali M. Smith, MD

3:05 pm
CD30-directed therapies
Anas Younes, MD
           
3:20 pm
Bcl-2 inhibitors
Wyndham H. Wilson, MD, PhD

3:35 pm
Metronomic therapy: Targeting angiogenesis
Jia Ruan, MD, PhD

3:50 pm     
Discussion

4:00 pm     
Adjourn

Imedex^®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 18.0 of AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This educational program is specifically designed for hematologists, oncologists, internists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) involved in and/or interested in lymphoma, myeloma and related plasma cell disorders and their management. No specialized knowledge or skill other than general familiarity with hematology or internal medicine is required for successful participation in this program.

The following educational objectives are outlined for the 2007 conference:

• Review updates in the biology of myeloma, lymphoma, and related plasma cell disorders
  
• Utilize new diagnostic and prognostic indicators in myeloma and lymphoma, and related plasma cell disorders
  
• Identify the most important genetic and molecular abnormalities of myeloma and lymphoma cells
  
• Implement the latest first-line therapies in myeloma and lymphoma, and related plasma cell disorders
  
• Improve management of relapsed/refractory disease in myeloma and lymphoma
  
• Employ state-of-the-art therapies for both early and advanced lymphomas
  
• Implement evidence-based management strategies for the various types and stages of lymphoma, myeloma and related plasma cell disorders
  
• Recognize both available new drugs as well as emerging therapies in the pipeline for the treatment of myeloma and lymphoma, and related plasma cell disorders

Click here to register for this program

REGISTRATION FEES
Physicians:
Discounted (If payment received by August 16, 2007) . . . . $345
Regular (If payment received by October 11, 2007) . . . . . . $445
Full/Onsite (If payment received after October 11, 2007) . . $545

Pharmacists*:
Discounted (If payment received by August 16, 2007) . . . . .$245
Regular (If payment received by October 11, 2007) . . . . . . $295
Full/Onsite (If payment received after October 11, 2007) . . .$345

Nurses/Residents/Students*. . . . . . . . . . . . . . . . . . . . . . . . $99

* Proof of eligibility must accompany registration

To Register: You may register online by October 11, 2007 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than October 11, 2007. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add $25 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the conference: 284 Lymphoma & Myeloma 2007. An attendee is not registered until full payment is received.

Wire to: Bank of America, ABA: 0260.0959.3, Account Info: Imedex, Inc., Account: 0000.0106.3308. If the wire originates outside the United States, please add this additional information: Clearing Bank: Bank of America, New York, Swift Code: BOFAUS3N, Clearing Account: 6550305831.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than October 11, 2007. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 11, 2007.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event program content is subject to change without notice.

The Waldorf=Astoria
301 Park Avenue
New York, New York 10022
Tel.: +1 (800) 925 3673
Fax: +1 (212) 872 7272
http://www.hilton.com/en/hi/groups/personalized/nycwawa_lym/index.jhtml

As one of the first “grand hotels” to combine luxurious elegance with a myriad of amenities and services, the Waldorf=Astoria has been world renowned for over a century. With a reputation for unparalleled hospitality and service, the Art Deco landmark beckons New Yorkers and visitors alike. Since 1893, The Waldorf=Astoria has epitomized the quintessential luxury hotel experience. Each spacious, individually decorated guest room and suite offers a rewarding union of timeless elegance and up-to-the-moment convenience, luxurious comfort and classic sophistication. The legendary shops of Fifth and Madison Avenues are only minutes away, as are numerous art galleries and specialty shops. The hotel itself is home to some of the world’s most luxurious boutiques.

This block is Sold Out!
For the convenience of attendees, a limited number of rooms have been reserved until September 24, 2007 at a discounted rate of $379 single/double occupancy, plus tax, currently at 13.38% and a $3.50 per night occupancy tax. This rate is not guaranteed outside the conference dates or after September 24, 2007. Internet users must enter the meeting promotional code: LYM.

New York Marriott East Side
525 Lexington Avenue & 49th Street
New York, New York 10017
Phone: +1 212 755 4000
www.nymarriotteastside.com

The NYC Marriott East Side Hotel in Midtown Manhattan is a magnificent 1924 treasure of rare distinction among New York City hotels. Enjoy the stylish contemporary decor of this gloriously restored classic midtown NYC hotel.

For the convenience of attendees, a limited number of rooms have been reserved until September 24, 2007 at a discounted rate of $389 single/double occupancy, plus tax, currently at 13.38% and a $3.50 per night occupancy tax. This rate is not guaranteed outside the conference dates or after September 24, 2007.

To reserve your room please contact the Marriott East Side Hotel reservations department at +1 212 755 4000 or visit the hotel’s conference reservations page at http://cwp.marriott.com/nycea/lymphomamyelomaconference/ to receive the group rate, callers must identify themselves as being with the Lymphoma & Myeloma 2007 group. Reservation requests received after September 24, 2007 may not be guaranteed the group rate.

          4325 Alexander Drive
          Alpharetta, GA 30022-3740 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com